T cells

Developed for: melanoma · Fanconi anemia
Investigated by: Adelson Medical Research · Baylor College of Medicine · California Institute for Regenerative Medicine (CIRM) · Center for Cell and Gene Therapy, Baylor College of Medicine · Karolinska University Hospital · Key Biologics, LLC
+5 more
· M.D. Anderson Cancer Center · National Cancer Institute (NCI) · Prometheus Laboratories · Samuel Strober · University of Texas, Southwestern Medical Center at Dallas

Trials 4

today NCT03292445 · Ph 0 NCT01946373 · Ph 1 NCT00338377 · Ph 2 NCT00586274 · Ph 1

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT03292445	Feb 2017 → Feb 2022	—	Samuel Strober	Unknown	No outcome recorded
Phase 12 trials
Phase 1	NCT01946373	Oct 2013 → Dec 2025	melanoma	Karolinska University Hospital	Unknown	No outcome recorded
Phase 1	NCT00586274	Mar 2002 → Jul 2009	Fanconi anemia	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 21 trial · 1 missed
Phase 2	NCT00338377	Feb 2006 → Feb 2030 expected	melanoma	M.D. Anderson Cancer Center	Active not recruiting	Missed primary

News releases announcing trial results or a regulatory action · 106

Date	Issuer	Release
2026-09-25	C4 Therapeutics, Inc.	Results C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting c4therapeutics.com ↗ Biomarker data from the first two patients showed that cemsidomide drives the expansion and activation of CD8+ effector memory T cells as measured by elevated HLA-DR and prevents T-cell exhaustion as measured by PD-1, TIM-3 and LAG3 expression.
2026-08-26	HaemalogiX Ltd	Results HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell haemalogix.com ↗ Following an initial infusion, the patient demonstrated that the treatment was well-tolerated, with no serious adverse events.
2026-08-14	Elicera Therapeutics	Results Correction - Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study – tumor responses in 10 of 11 patients evaluated to date elicera.com ↗ The correct information is that all three patients achieved disease control and that two of them obtained an objective tumor response, of which one was a complete metabolic response.
2026-08-11	Elicera Therapeutics	Results Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study – tumor responses in 10 of 11 patients evaluated to date elicera.com ↗ No dose-limiting toxicities (DLTs) have been observed, and the treatment has been well tolerated to date.
2026-07-21	Enterome	Results Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting enterome.com ↗
2026-06-15	Enterome	Results Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity enterome.com ↗ EO2463 rapidly induced expansion of EO2463-mimic and B cell target peptide-specific CD8 T cells, predominantly displaying an effector memory phenotype cross-reactive with cancerous B-cell lineage markers.
2026-03-17	HaemalogiX Ltd	Regulatory Green Light for First-in-Human Trial of KMCAR™ T-cell Therapy in Multiple Myeloma haemalogix.com ↗ Clinical Trial Approval (CTA) granted by Australia’s Therapeutic Goods Administration (TGA) for KMCAR™ T-cell, a first-in-human CAR-T cell therapy for multiple myeloma, the second most common blood cancer worldwide
2026-03-06	Elicera Therapeutics	Results Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients elicera.com ↗ New data shows complete metabolic responses from the first two patients treated in cohort 3 (the highest dose level to date), as well as follow-up data from patients in cohorts 1 and 2.
2026-02-11	Elicera Therapeutics	Results Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study elicera.com ↗ The poster presentation will highlight complete metabolic response in four of six patients treated with the iTANK-armed CAR T-cell therapy ELC-301 in the first two cohorts of the study.
2025-09-18	Shenzhen MagicRNA Biotechnology Co., Ltd	Results MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine. magicrna.com ↗
2025-09-12	CARsgen Therapeutics Co., Ltd.	Results Preliminary Clinical Data of Allogeneic CD19/CD20 CAR-T Product for Mantle Cell Lymphoma Reported at Academic Conference carsgen.com ↗ After CT1190B infusion, both patients experienced short-term cytopenia and cytokine release syndrome (CRS), which improved with supportive care.
2025-07-07	Mustang Bio, Inc.	Regulatory Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma mustangbio.com ↗ today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to Mustang for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of recurrent diffuse and anaplastic astrocytoma (astrocytomas) and glioblastoma (GBM).
2025-06-30	Faron Pharmaceuticals Ltd	Results Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action faron.com ↗ sClever-1, released by macrophages and endothelial cells, was found to bind to activated T cells, impairing their signaling and promoting the differentiation of suppressive T cells, contributing to tumor immune evasion.
2025-05-30	Agenus Inc.	Results Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer agenusbio.com ↗ Activating these typically 'cold' tumors and driving a strong T cell response suggests that botensilimab has the potential to overcome resistance and improve patient outcomes.
2025-05-22	Elicera Therapeutics	Results Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy elicera.com ↗ Preliminary data show that two out of three treated patients had no active lymphoma detected on specialized scans, achieving a complete metabolic response.
2025-05-22	Nanjing Legend Biotech Co.	Results Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT legendbiotech.com ↗ dnTGFβRII-Armored DLL3-Targeted CAR-T Cells Maintain TGFβ Resistance with Early Signals of T-Cell Exhaustion Modulation After Expansion in SCLC
2025-05-15	BrainChild Bio, Inc	Regulatory FDA grants Regenerative Medicine Advanced Therapy designation forBrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors brainchildbio.com ↗
2025-05-12	Biosceptre	Results Biosceptre's BRiDGECAR™ Platform Recognised at Two Major Global Conferences! biosceptre.com ↗ This study demonstrates how BRiDGECAR™ T-cells outperform conventional CAR-Ts in AML models, offering superior cytotoxicity, better fitness, and long-term persistence via a modular, therapeutic antibody-adaptor approach.
2025-04-25	IO Biotech	Results IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 iobiotech.com ↗ IO102-IO103, a dual-antigen vaccine targeting IDO1+ and PD-L1+ cells, generated strong T-cell responses and modulated the tumor microenvironment in two mouse models, where IDO1 and PD-L1 vaccine each contributed differently to control tumor growth.
2025-04-25	Molecular Partners AG	Results Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 molecularpartners.com ↗ Preclinical proof-of-concept data on Molecular Partners’ conditionally activated CD3 Switch-DARPin shows it activates T cells specifically in the presence of cells co-expressing MSLN and epithelial cell adhesion molecule (EpCAM), increasing tumor specificity.
2025-04-22	BrainChild Bio, Inc	Regulatory FDA grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors brainchildbio.com ↗ FDA grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors
2025-02-24	Cellectis S.A.	Results Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 cellectis.com ↗ CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN-edited allogeneic CAR T-cells without associated IL-2 toxicity
2025-02-24	Agenus Inc.	Results Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting agenusbio.com ↗ The addition of MiNK’s allogeneic iNKT therapy, agenT-797, to BOT/BAL drove robust immune activation, including elevated interferon-gamma (IFNγ) levels, indicating potent systemic engagement and overcoming immunosuppressive pathways in PD-1–refractory gastric tumors.
2025-02-21	Estrella Biopharma, Inc.	Results Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort estrellabio.com ↗ Preliminary data from this cohort demonstrated a favorable safety profile, with no dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) observed.
2025-01-21	Elicera Therapeutics	Results Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference elicera.com ↗ The first patient showed a complete response (CR) at the first follow-up, one month after completing treatment, with no serious side effects observed.
2024-12-13	BriaCell Therapeutics Corporation	Results BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT(TM) Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer briacell.com ↗ BriaCell employed this advanced imaging technology as a precision diagnostic tool to monitor patients’ immune system responses in its phase 2 study, establishing the ability of the Bria-IMT™ regimen to induce tumor infiltration with CD8+ “killer” T cells.
2024-11-14	Lion TCR Pte. Ltd.	Regulatory Lion TCR Secures China NMPA IND Approval for GZL-016, an Innovative mRNA-based TCR-T Cell Therapy for Hepatocellular Carcinoma liontcr.com ↗ On November 14, 2024, Lion TCR, a clinical-stage T-cell immunotherapy company, announced that it has received clearance from the China National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application for GZL-016.
2024-11-13	Inovio Pharmaceuticals	Results Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial inovio.com ↗ In the recent immunology study, INO-3107 induced the expansion of both existing and new clonal T cells that travel from the blood to the papilloma and airway tissues.
2024-10-17	Nektar Therapeutics	Results Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia nektar.com ↗ The data published in Blood showed favorable efficacy with eight out of nine patients (89%) whom successfully received CAR19-22 followed by NKTR-255 achieving measurable residual disease (MRD) negative remission.
2024-10-15	Tevogen Bio Inc	Results Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use tevogen.com ↗ Patients in the treatment group had symptom improvement and resolution more consistently, and in many cases, faster, than those in the observation group.
2024-09-27	Estrella Biopharma, Inc.	Results Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells estrellabio.com ↗ today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells.
2024-09-03	Cellectis S.A.	Results Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety cellectis.com ↗ Importantly, intratumoral treatment effectively reduced local and distant tumors of large size using low doses of multi-armored MUC1 CAR T-cells.
2024-08-26	Cellectis S.A.	Results Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors cellectis.com ↗ The resultant SMART Dual CAR T-cells efficiently infiltrate and efficiently target triple-negative breast tumors in physiologically relevant mice models, with no observable on-target, off-tumor toxicity.
2024-06-14	Wugen, Inc.	Results Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress wugen.com ↗ Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announces positive Phase 2 results for the company’s investigational anti-CD7 CAR-T therapy, WU-CART-007 (“W-T7”), in patients with relapsed/refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL).
2024-05-14	Celularity Incorporated	Results Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy celularity.com ↗ CAR-T cells generated from its T-Cell platform retained stemness, maintained longer telomeres, and were more resistant to both exhaustion and immune checkpoint upregulation.
2024-03-07	Celularity Incorporated	Results Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells celularity.com ↗ These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9 th , 2024.
2024-03-04	RS Oncology LLC	Results Recent advancements in treating malignant pleural mesothelioma and why localized treatment could be advantageous rsoncology.com ↗
2024-02-09	Elicera Therapeutics	Regulatory Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma elicera.com ↗
2023-12-22	Elicera Therapeutics	Regulatory Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application elicera.com ↗ Elicera Therapeutics has now generated preclinical validation data, confirming high and consistent quality of its active pharmaceutical substance, and submitted the complementary information to the regulatory agency.
2023-12-12	BioOra Limited	Results Clinical Trial Results Support BioOra’s Automated CAR T-Cell Manufacturing for Next Phase bioora.com ↗ New clinical results from the ENABLE phase 1 trial have shown strong safety and efficacy outcomes for a third-generation CD19-specific CAR T-cell therapy—marking a major step forward for the future of automated cancer immunotherapy in New Zealand and beyond.
2023-12-11	Wugen, Inc.	Results Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting wugen.com ↗ Overall, WU-CART-007 demonstrated a manageable safety profile: No cases of Graft versus Host Disease (GvHD), prolonged T-cell aplasia, or prolonged pancytopenia in the absence of disease were observed.
2023-12-11	Atara Biotherapeutics	Results Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting atarabio.com ↗ Compared to an autologous CD20/CD19 CAR-T benchmark, the ATA3431 preclinical data demonstrate potent antitumor activity, long-term persistence, and superior tumor growth inhibition.
2023-12-06	BriaCell Therapeutics Corporation	Results BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit briacell.com ↗ Today’s posters highlight the activation of cancer fighting immune cells by the Bria-IMT™ combination regimen that was identified using leading-edge technologies.
2023-10-31	Coeptis Therapeutics	Results Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 coeptis.com ↗ Further, in another leukemia model targeting the CD20 antigen, SNAP-CAR T cells showed significant inhibition of tumor growth.
2023-10-13	Anixa Biosciences, Inc.	Results Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial anixa.com ↗ All three patients in the first cohort received the same dose of engineered T-cells, with no dose-limiting toxicities observed.
2023-09-13	PeproMene Bio, Inc.	Results PeproMene Bio, Inc. Announced Completion of the First Dose Cohort and Opening of the Second Dose Cohort in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) pepromenebio.com ↗ The Overall Response Rate is 100% (two Complete Response and one Partial Response) at one-month post treatment.
2023-08-14	Alaunos Therapeutics	Results Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives alaunos.com ↗ The trial showed that the Company’s T-cells were generally well-tolerated in all evaluable participants and achieved an 83% disease control rate in evaluable patients with metastatic, refractory solid tumors.
2023-07-10	Hemogenyx Pharmaceuticals LLC	Regulatory Full FDA Review for HEMO-CAR-T IND hemogenyx.com ↗ The letter contains a detailed description of the rationale for the decision to put HEMO-CAR-T IND on CH.
2023-06-12	Mendus	Results Mendus presents comprehensive ADVANCE II immunomonitoring data at the EHA Annual Meeting 2023 mendus.com ↗ The data demonstrate that vididencel treatment led to increased levels of activated, cancer-killing T cells and reduced levels of inhibitory, immune-suppressive T cells in the majority of patients.
2023-06-09	Wugen, Inc.	Results Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress wugen.com ↗ The Objective Response Rate (ORR) in efficacy evaluable patients was 57% overall (4/7), including 2 Complete Responses (CR), 1 morphological leukemia-free state (MLFS), and 1 Partial Response (PR).
2023-05-18	Orchard Therapeutics	Results Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications orchard-tx.com ↗ Data from transplanted mice show that the preferential expression of CAR in HSC-derived regulatory T cells in vivo does not significantly alter the development, phenotype or function of these suppressive immune cells.
2023-05-12	Cellectis S.A.	Results Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors cellectis.com ↗ May 12, 2023 - New York, NY – Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Frontiers Bioenginnering, demonstrating the efficacy of its TALEN® engineered FAP UCART-cells in cancer-associated fibroblast (CAF) depletion, reduction of desmoplasia and tumor infiltration.
2023-04-28	Elicera Therapeutics	Regulatory Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study) elicera.com ↗ Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced that it has received approval from the Swedish Medical Products Agency (MPA) on its Clinical Trial Application (CTA) to evaluate its CAR T-cell therapy, ELC-301, in treatment of patients with B-cell lymphoma (CARMA-study), conditional on certain further validations of its GMP-process.
2023-04-17	Bright Peak Therapeutics Inc	Results Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional αPD1-IL18 Immunocytokine brightpeaktx.com ↗ T cells co-expressing PD-1 and IL-18 receptors are highly enriched in the tumor microenvironment (TME) versus peripheral blood, providing rationale for tumor-selective targeting with BPT567
2023-01-26	Elicera Therapeutics	Regulatory Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma elicera.com ↗ today announced that it has submitted a Clinical Trial Application (CTA) to the Swedish Medical Products Agency and the Ethics Committee´ to evaluate its CAR T-cell therapy, ELC-301, in treatment of B-cell lymphoma.
2022-11-10	Celularity Incorporated	Results Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting celularity.com ↗ CYCART-19 treatment 7 days post onCARlytics infection showed significant tumor regression compared to onCARlytics or T cells alone in a mouse xenograft model of triple-negative breast cancer.
2022-11-07	Obsidian Therapeutics, Inc.	Results Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022 obsidiantx.com ↗ T cells expressing IL15 and either IFN-alpha or IL18 showed improved efficacy and TME remodeling, and combining IL15 with TNFSF-X resulted in growth arrest of syngeneic melanoma tumors in mice.
2022-08-18	CARsgen Therapeutics Co., Ltd.	Results Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology carsgen.com ↗ The published case reported a patient with advanced HCC who achieved a complete response (CR) and a long survival period after the combination therapy of CAR-GPC3 T-cell plus sorafenib.
2022-05-27	OriCell Therapeutics Co., Ltd.	Results OriCell Releases Full Abstract of its 2022 ASCO Oral Report oricell.com ↗ Responses were durable and deepened overtime with 100% ORR and 100% MRD negative rate, including BCMA CAR-T relapsed patients, all patients are progression free and followed without additional therapy at the cutoff date.
2022-05-16	Cellectis S.A.	Results Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT cellectis.com ↗ Cellectis’ research suggested that ΔTRACCARΔB2MHLAE T-cells evade NK cell and alloresponsive T-cell attacks and showed prolonged antitumor activity in the presence of cytotoxic levels of NK cells.
2022-04-14	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine oncolyticsbiotech.com ↗ today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with chimeric antigen receptor (CAR) T cell therapy in solid tumors.
2022-04-07	Synthekine	Results Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting synthekine.com ↗ Here we demonstrate the ability of our orthogonal IL-2 system to enhance the anti-tumor activity and persistence of anti-glypican 3 (GPC3) CAR T cells in human hepatocellular cancer models leading to tumor rejection in the majority of mice.
2022-04-04	Elicera Therapeutics	Results Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies elicera.com ↗ Proof-of-concept data presented in the publication also indicate that the iTANK-platform is universally compatible with other CAR T-cell therapies.
2022-02-15	Mustang Bio, Inc.	Results Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium mustangbio.com ↗ Three patients were treated at the 100M cell dose with no DLTs.
2022-01-04	Equillium	Results Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis equilliumbio.com ↗ The newly published data supports Equillium’s research of itolizumab, a first-in-class anti-CD6 monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively inhibit pathogenic T effector cells.
2021-12-23	Lion TCR Pte. Ltd.	Regulatory Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma liontcr.com ↗ This Fast Track Designation provides Lion TCR with an expedited path towards the regulatory approval for its leading investigational product, LioCyx-M004, which is being developed as a potential first-in-class drug for HBV-related HCC.
2021-12-15	Ocugen	Results New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination ocugen.com ↗ In the analysis, COVAXIN™ (BBV152) generated T-cells against both spike and nucleocapsid proteins in nearly 85 percent of subjects that persisted for at least 6 months.
2021-12-09	Atara Biotherapeutics	Results Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021 atarabio.com ↗ Importantly, ATA2271 CAR T-cells persisted in patients’ peripheral blood for greater than four weeks and was associated with upregulated effector cytokines.
2021-11-12	Beam Therapeutics Inc.	Results Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies beamtx.com ↗ today announced new preclinical research demonstrating the ability of the company’s multiplex edited CAR T cells to target CD5-positive tumors, leading to tumor clearance in vivo.
2021-09-01	iCell Gene Therapeutics	Results iCell Gene Therapeutics Announces cCAR-T Clinical Publication in Stem Cell Reviews and Reports Journal. icellgene.com ↗ After a single infusion of CD19-BCMA cCAR the patient achieved undetectable levels of autoantibodies that mediate SLE, successfully treating the patient’s SLE for 2 years without the need for additional medications.
2021-08-13	Nanjing IASO Biotechnology Co., Ltd.	Results IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in Molecular Therapy iasobio.com ↗
2021-06-09	Adaptive Biotechnologies	Results New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern adaptivebiotech.com ↗ Post-vaccination, results showed that the levels of neutralizing antibodies were diminished against the variants, but that the T-cell immune response was preserved, suggesting T cells may provide protection against these emerging strains.
2021-05-11	Phio Pharmaceuticals Inc.	Results Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells phiopharma.com ↗ Compared to untreated HER2CART cells, HER2CART cells treated with PH-762 showed a statistically significant and durable inhibition of tumor growth.
2021-04-10	Molecular Partners AG	Results Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR molecularpartners.com ↗ We believe these data support the designed capability of this candidate to kill a broader population of AML cells while decreasing risk of toxicity.
2021-03-17	GT Biopharma, Inc.	Results GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results gtbiopharma.com ↗ Targeted delivery of IL-15 to NK cells via GTB-3550 TriKE showed preferential proliferation of NK cells and significantly less effect on CD8+ and CD4+ T-cells.
2021-03-02	AvenCell Europe GmbH	Results GEMoaB Announces Publication of Clinical Data From Ongoing Phase I Study of Their Lead Asset UniCAR-T-CD123 in Relapsed/Refractory AML in “Blood” avencell.com ↗ The interim data of UniCAR-T-CD123 in rrAML, published online ahead of print as a letter in “Blood” (Wermke et al. 2021, https://doi.org/10.1182/blood.2020009759 ), demonstrate that UniCAR-T-CD123 in rrAML is well-tolerated with rapid recovery of hematopoiesis and encouraging early efficacy.
2021-02-23	Oncolytics Biotech	Results Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors oncolyticsbiotech.com ↗ These synergistic immune effects were specific to pelareorep, as intravenous boosting with VSV did not augment CAR/Pela therapy or prevent the growth of recurrent tumors.
2021-02-03	Vaxart	Results Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate vaxart.com ↗ Our vaccine induced a high percentage of responding CD8+ T cells against both Spike (S) and Nucleoprotein (N) proteins, which may provide protection against variants with alterations in the faster-changing S protein.
2021-02-03	AvenCell Europe GmbH	Results GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd EHA-EBMT European CAR T-Cell Meeting avencell.com ↗ Poster presentation confirms re-activation and expansion of UniCAR-T cells during 2nd treatment cycle with Targeting Module TM123
2021-01-07	AvenCell Europe GmbH	Results GEMoaB Announces Clinical Data Presentations on Their Lead Asset UniCAR-T-CD123 in relapsed/refractory AML at the Upcoming EHA-EBMT 3rd European CAR T-Cell Meeting avencell.com ↗ The Phase I data of UniCAR-T-CD123 in rrAML presented at the congress highlight the unique product profile of UniCAR-T-CD123 in heavily pretreated rrAML patients as well as the key features of GEMoaB’s rapidly switchable universal CAR-T platform, UniCAR.
2020-12-21	GT Biopharma, Inc.	Results GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT gtbiopharma.com ↗ Targeted delivery of IL-15 to NK cells via GTB-3550 TriKE™ therapy showed preferential proliferation of NK cells, significantly less effect on CD8+ T-cells, and no observed toxicity at 25x the previous reported MTD for continuous infusion of recombinant human IL-15.
2020-10-05	Corvus Pharmaceuticals, Inc.	Results New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19 corvuspharma.com ↗
2020-09-09	Pfizer	Results Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19 pfizer.com ↗ The BNT162b2 vaccine candidate induced SARS-CoV-2 neutralizing antibodies in rhesus macaques, pseudovirus neutralizing antibodies in mice, and strong, antigen-specific CD4+ and CD8+ T cells in mice and macaques
2020-08-24	Compass Therapeutics	Results Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models compasstherapeutics.com ↗ Data Demonstrate Overexpression of BTN3A1 is Associated with a Poor Prognosis in Ovarian Cancer and the Ability of CTX-2026 to Engage both Gamma Delta and Alpha Beta T Cells to Overcome the Immunosuppressive Tumor Microenvironment
2020-05-12	Mustang Bio, Inc.	Results Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy mustangbio.com ↗ CS1 Targeted CAR-T Cells (MB-104) for the Treatment of Multiple Myeloma Shows Antitumor Activity Sparing Normal T-Cells Despite the Common Expression of CS1
2019-09-30	Faron Pharmaceuticals Ltd	Results MATINS poster presentation at ESMO Congress faron.com ↗ The patients also increased circulating CD8+ T cells and CD8+/CD4+ ratio, decreased regulatory T-cells (T-regs) or had a substantial increase in mobile natural killer (NK) cells in the blood, all signs of this desired immune activation.
2019-08-27	Imcyse SA	Results Imcyse reports successful first-in-human phase 1B study in type 1 diabetes with IMCY-0098 imcyse.com ↗ In addition, promising early clinical trends and relevant immunological responses were observed, including the detection of cytolytic CD4 T cells.
2019-07-12	Faron Pharmaceuticals Ltd	Results MATINS study update faron.com ↗ A new discovery following study of subjects’ cellular responses, has been the identification of an increase in interferon gamma (IFNγ) production by the host immune system, accompanied by an increase in circulating Th1 differentiated CD4+ and CD8+ T cells.
2019-03-27	Enterome	Results Enterome to present data on its innovative microbiome-derived molecular mimicry approach to cancer immunotherapy at AACR 2019 enterome.com ↗ Furthermore, adoptive transfer of T cells from mice immunized with onco-mimics into tumor-engrafted nude mice led to tumor control in the presence of checkpoint inhibitors.
2018-12-03	Atara Biotherapeutics	Results Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting atarabio.com ↗ Another important study presents positive Phase 2 clinical results in patients with EBV+ PTLD involving the CNS.
2018-11-01	Atara Biotherapeutics	Results Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018 atarabio.com ↗ The investigators created mutated CAR T cells with mutations in intracellular co-stimulatory domains (PYAP-only CAR T-cell) resulting in reduced cytokine secretion, but maintained cytotoxic activity compared to non-mutated (CD28 CAR T cells).
2018-08-08	Bavarian Nordic	Results Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine bavarian-nordic.com ↗
2018-06-11	Theralase® Technologies Inc.	Results Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours theralase.com ↗ Theralase researchers have also observed an increased number of anti-tumour specific immune cells in brain tissue treated with Rutherrin® versus ALA treated animals.
2018-04-18	Xencor, Inc.	Results Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting xencor.com ↗ Data show that the engineered complex enhanced the duration and magnitude of T and NK cell proliferation in vitro and in vivo.
2018-03-16	Carina Biotech Limited	Results Adelaide’s Carina Makes Killer Cells to Cure Cancer carinabiotech.com ↗ Carina Biotech chief executive Dr Justin Coombs said laboratory results for their type of Chimeric Antigen Receptor T-cells or CAR T-cells “were really quite stunning”.
2018-01-26	Verastem, Inc.	Results Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model verastem.com ↗ The mice that had received anti-OX40 alone grew new tumors upon A20 re-challenge, however, all mice that had received duvelisib + anti-OX40 did not grow tumors upon re-challenge and showed elevated memory T cells in blood and spleen.
2017-12-11	AbbVie	Results IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition abbvie.com ↗ In addition, the data also showed that ibrutinib preserved immune memory and Th1 T cells, which suggests the potential for additional treatment benefit.
2017-05-04	Alligator Bioscience AB	Results Alligator Bioscience presents promising immuno-oncology data at US conference; – Strong new preclinical findings for ADC-1013 and ATOR-1015 alligatorbioscience.se ↗ ATOR-1015 activated effector T-cells and suppressed regulatory T-cells in tumors, but not elsewhere in the body.
2016-12-05	Omeros Corporation	Results Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy omeros.com ↗ Moreover, GPR174 inhibition statistically significantly reduced by approximately 40 percent the population of Tregs, a subset of T-cells elevated in a large number of cancers.
2016-12-03	Atara Biotherapeutics	Results Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 atarabio.com ↗ Response Rate: 73.3% with 6 complete responses (CR) and 5 partial responses (PR).
2016-08-04	Alaunos Therapeutics	Results First-In-Human Trials using Non-Viral Sleeping Beauty System to Express CD19-Specific CAR in T cells Published in Journal of Clinical Investigation alaunos.com ↗ Six of the seven patients remain in complete remission (CR) and the 30-month progression-free survival (PFS) and overall survival (OS) rates were 83.3% and 100%, respectively.
2016-06-06	Atara Biotherapeutics	Results Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate atarabio.com ↗ This data included safety and efficacy of EBV-CTL in the treatment of 14 patients with recurrent metastatic nasopharyngeal carcinoma (NPC).
2016-02-17	Parvus Therapeutics, Inc.	Results Parvus Therapeutics’ Nanotechnology Treatment Reprograms Immune Cells to Reverse Autoimmune Disease, as Published in Nature parvustx.com ↗ pMHC class II Navacims expanded cognate CD4+ T-cells that consistently have a TR1-like, regulatory T cell surface phenotype, transcriptional pattern and cytokine profile (mouse=human TR1 cells) systemically.
2015-09-01	Alaunos Therapeutics	Results ZIOPHARM Announces Cancer Research Publication of Study Demonstrating Preferential Targeting of Solid Tumor Cells by Modified CAR T Cells alaunos.com ↗
2015-08-03	Protalix	Results Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF protalix.com ↗ Fluorescence-activated cell sorting analysis (FACS) was performed using various antibodies for surface markers, and it was observed that all three dosages of PRX-106 promoted the induction of various subsets of T cells, some of which are correlated with anti-inflammatory response.
2010-04-05	Biogen	Results Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology biogen.com ↗ The second focuses on daclizumab’s effect on the balance of regulatory and activated T-cell (immune cell) numbers in people with MS ( Changes in Circulating Tregs Parallel Reductions in Activated T Cells During Daclizumab Treatment of MS – P04.193).

All press releases naming this drug 120 releases

Date	Issuer	Release
Show all 120 releases opens the full record — a long page

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	T cells	“At least 30 days after the stem cell infusion, patients will be dosed with T cells.” NCT00586274 ↗ 3 NCT03292445 ↗ NCT01946373 ↗ NCT00338377 ↗
Modality	Cell therapy	“adoptive cell transfer” NCT00338377 ↗
Route	Intravenous	“by vein infusion over 30-60 minutes” NCT00338377 ↗